Golden State Equity Partners Has $459,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Golden State Equity Partners reduced its holdings in Regeneron Pharmaceuticals by 39.5%, owning 875 shares worth $459,000 at the end of the second quarter.
• Multiple institutional investors made significant adjustments to their positions in REGN, with GAMMA Investing LLC increasing its holdings by an astounding 89,825% during the first quarter.
• Despite a recent decline in stock price, Wall Street analysts maintain a consensus rating of "Moderate Buy" with a target price averaging $817.67 for the stock.

Golden State Equity Partners cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 39.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 875 shares of the biopharmaceutical company's stock after selling 571 shares during the period. Golden State Equity Partners' holdings in Regeneron Pharmaceuticals were worth $459,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $343,764,000. Pacer Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $127,215,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on REGN shares. Royal Bank Of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a report on Friday, August 1st. Finally, Citigroup restated a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Down 4.7%

REGN stock opened at $567.89 on Wednesday. The stock has a market capitalization of $60.19 billion, a P/E ratio of 14.31, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,080.00. The firm has a 50-day moving average price of $568.67 and a 200-day moving average price of $573.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.56 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.